- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05065372
MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes (MANATEE-T1D)
August 21, 2023 updated by: University of Colorado, Denver
Diabetic kidney disease and cardiovascular disease remain the leading causes of morbidity and mortality in people with type 1 diabetes and are exacerbated with longer duration of diabetes and time outside goal glycemic range.
Yet, type 1 diabetes is a complex disease with pathophysiology that extends beyond beta-cell injury and insulin deficiency to include insulin resistance and renal vascular resistance, factors that accelerate cardiovascular disease risk.
We have shown that metformin improved peripheral insulin sensitivity and vascular stiffness in youth with type 1 diabetes on multiple daily insulin injections or standard insulin pumps.
However, metformin's effect on kidney and endothelial outcomes, and the effects of type 1 diabetes technologies, with or without metformin, on any cardiovascular or kidney outcome, remains unknown.
Automated insulin delivery systems combine an insulin pump, continuous glucose monitor, and control algorithm to modulate background insulin delivery and decrease peripheral insulin exposure while improving time in target range and reducing hypoglycemia.
We hypothesize that automated insulin delivery systems, particularly when combined with metformin, may modulate renal vascular resistance and insulin sensitivity, thereby impacting cardiometabolic function.
MANATEE-T1D is a randomized, double-blind, placebo-controlled trial of 4 months of metformin 2,000 mg daily in 40 youth aged 12-21 years with type 1 diabetes on automated insulin delivery systems vs. 20 control youth with type 1 diabetes on multiple daily injections plus a continuous glucose monitor which will assess for changes in calculated renal vascular resistance and gold standard measures of whole-body and adipose insulin sensitivity, arterial stiffness, and endothelial function.
Study Overview
Status
Recruiting
Conditions
Study Type
Interventional
Enrollment (Estimated)
60
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Lucy Hall, MS
- Phone Number: 720-777-2692
- Email: Lucy.Hall@childrenscolorado.org
Study Contact Backup
- Name: Kalie Tommerdahl, MD
- Phone Number: 720-777-5898
- Email: Kalie.Tommerdahl@childrenscolorado.org
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Recruiting
- University of Colorado Anschutz Medical Campus
-
Contact:
- Lucy Hall, MS
- Phone Number: 720-777-2692
- Email: Lucy.Hall@childrenscolorado.org
-
Contact:
- Kalie Tommerdahl, MD
- Phone Number: 720-777-6128
- Email: Kalie.Tommerdahl@childrenscolorado.org
-
Principal Investigator:
- Kalie Tommerdahl, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
12 years to 21 years (Child, Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Youth with pancreatic antibody positive type 1 diabetes
- Age 12-21 years
- Use of an automated insulin delivery system or multiple daily insulin injections plus a continuous glucose monitor for > 6 months
- Pubertal
- Weight > 54 kg and BMI > 5th percentile for age and sex
- Hemoglobin A1c < 11%
- No recent episodes of diabetic ketoacidosis (DKA) or hyperglycemic hyperosmolar syndrome (HHS)
Exclusion Criteria:
- Blood pressure > 140/90 mm Hg
- Anemia
- Estimated glomerular filtration rate < 60 mL/min/1.73 m2 or serum creatinine > 1.2 mg/dL or history of urinary albumin to creatinine ratio ≥ 300mg/g or history of acute kidney injury
- Use of anti-diabetic agents except insulin, angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARB's), diuretics, daily non-steroidal anti-inflammatory drugs (NSAIDs) or aspirin, sulfonamides, procaine, thiazosulfone or probenecid
- Seafood or iodine allergy
- Pregnancy or breast feeding for females
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Metformin plus automated insulin delivery system
Some participants with type 1 diabetes using an automated insulin delivery system will be randomized to receive treatment with metformin and will undergo RPF (Aminohippurate Sodium Injections 20%), GFR (Iohexol Inj 300 MG/ML), and insulin sensitivity (hyperinsulinemic-euglycemic clamp) assessments, in additional to assessments of cardiovascular and endothelial function.
|
Agent used to modify insulin sensitivity
Other Names:
Diagnostic aid/agent used to measure renal plasma flow and calculate renal vascular resistance
Other Names:
Diagnostic aid/agent used to measure glomerular filtration rate
Other Names:
|
Placebo Comparator: Placebo plus automated insulin delivery system
Some participants with type 1 diabetes using an automated insulin delivery system will be randomized to receive treatment with a placebo pill which is identical in appearance to the metformin pill and will undergo RPF (Aminohippurate Sodium Injections 20%), GFR (Iohexol Inj 300 MG/ML), and insulin sensitivity (hyperinsulinemic-euglycemic clamp) assessments, in additional to assessments of cardiovascular and endothelial function.
|
Diagnostic aid/agent used to measure renal plasma flow and calculate renal vascular resistance
Other Names:
Diagnostic aid/agent used to measure glomerular filtration rate
Other Names:
Identical to Metformin Hcl 1000Mg Tab but without metabolic effects
|
Other: Multiple daily insulin injections plus continuous glucose monitor
Participants with type 1 diabetes using multiple daily injections plus a continuous glucose monitor will not be randomized to receive medication treatment but will undergo RPF (Aminohippurate Sodium Injections 20%), GFR (Iohexol Inj 300 MG/ML), and insulin sensitivity (hyperinsulinemic-euglycemic clamp) assessments, in additional to assessments of cardiovascular and endothelial function.
|
Diagnostic aid/agent used to measure renal plasma flow and calculate renal vascular resistance
Other Names:
Diagnostic aid/agent used to measure glomerular filtration rate
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Renal vascular resistance
Time Frame: 4 months
|
Renal plasma flow will be measured by para-aminohippurate clearance and used to calculate renal vascular resistance
|
4 months
|
Glomerular filtration rate
Time Frame: 4 months
|
Measured by iohexol clearance
|
4 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Arterial stiffness
Time Frame: 4 months
|
Measured by SphygmoCor
|
4 months
|
Endothelial function
Time Frame: 4 months
|
Measured by EndoPAT
|
4 months
|
Insulin sensitivity
Time Frame: 4 months
|
Measured by hyperinsulinemic-euglycemic clamp
|
4 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 1, 2022
Primary Completion (Estimated)
January 1, 2026
Study Completion (Estimated)
July 31, 2026
Study Registration Dates
First Submitted
September 13, 2021
First Submitted That Met QC Criteria
September 22, 2021
First Posted (Actual)
October 4, 2021
Study Record Updates
Last Update Posted (Actual)
August 22, 2023
Last Update Submitted That Met QC Criteria
August 21, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Immune System Diseases
- Autoimmune Diseases
- Urologic Diseases
- Endocrine System Diseases
- Diabetes Complications
- Hyperinsulinism
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Hypersensitivity
- Cardiovascular Diseases
- Diabetes Mellitus
- Kidney Diseases
- Diabetes Mellitus, Type 1
- Diabetic Nephropathies
- Insulin Resistance
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Metformin
Other Study ID Numbers
- 21-3483
- K23HL159292 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Diseases
-
Medical College of WisconsinRecruitingCardiovascular Diseases | Cardiovascular Risk Factor | Cardiovascular HealthUnited States
-
Hospital Mutua de TerrassaCompleted
-
Oregon Health and Science UniversityCompletedCardiovascular Disease | Cardiovascular Risk FactorsUnited States
-
Women's College HospitalUniversity Health Network, Toronto; Sunnybrook Health Sciences Centre; Brigham... and other collaboratorsUnknownCARDIOVASCULAR DISEASESCanada, United States
-
Groupe Hospitalier Paris Saint JosephTerminatedCARDIOVASCULAR DISEASESFrance
-
University of FloridaUniversity of Alabama at Birmingham; Brown UniversityCompletedCardiovascular Disease | Psychosocial Influence on Cardiovascular DiseaseUnited States
-
Nanjing Medical UniversityRecruiting
-
Centre Hospitalier Universitaire de la RéunionRecruitingCardiovascular DiseaseFrance
-
National Heart, Lung, and Blood Institute (NHLBI)RecruitingCardiovascular DiseaseUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)RecruitingCardiovascular DiseaseUnited States
Clinical Trials on Metformin Hcl 1000Mg Tab
-
Chong Kun Dang PharmaceuticalCompletedDiabetes Mellitus, Type IIKorea, Republic of
-
Dong Wha Pharmaceutical Co. Ltd.Completed
-
LG ChemCompletedHealthy Male VolunteersKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedDiabetes Mellitus, Type IIKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedDiabetes Mellitus, Type 2Korea, Republic of
-
LG Life SciencesCompletedType 2 DiabetesKorea, Republic of
-
Ain Shams UniversityUnknown
-
Handok Inc.CompletedHealthy VolunteersKorea, Republic of
-
American University of Beirut Medical CenterRecruiting